youtube_live
Q3 2026 earnings • 1:30 PM tomorrow
See detailschevron_right
KYNB:NASDAQ
Kyntra Bio Inc
$3.44
arrow_downward
-6.01%(-0.22) 1D
Nov 13, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
$3.63
High
$3.99
Low
$3.34
Mkt. cap
13.93M
Avg. vol.
25.03K
Volume
13.83K
P/E ratio
0.08
52-wk high
$9.70
52-wk low
$3.34
EPS
$45.30
Beta
1.08
Shares outstanding
4.05M
No. of employees
34
Open
$3.63
High
$3.99
Low
$3.34
Mkt. cap
13.93M
Avg. vol.
25.03K
Volume
13.83K
P/E ratio
0.08
52-wk high
$9.70
52-wk low
$3.34
EPS
$45.30
Beta
1.08
Shares outstanding
4.05M
No. of employees
34
News stories
From web sources and news partners
TradingView
·
1 day ago
Kyntra Bio, Inc. expected to post a loss of $3.55 a share - Earnings Preview
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
FoundedJan 1, 1993
HeadquartersSan Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Websitekyntrabio.com